Successful Treatment of Antifungal Combination Therapy with Inhaled Liposomal Amphotericin B and Oral Voriconazole for Intractable Chronic Progressive Pulmonary Aspergillosis

Intern Med. 2021 Aug 1;60(15):2465-2468. doi: 10.2169/internalmedicine.6305-20. Epub 2021 Mar 8.


We experienced a case of the successful treatment of intractable pulmonary aspergillosis with inhaled liposomal amphotericin B (L-AMB) and oral voriconazole (VRCZ). A 52-year-old man was admitted to our hospital with a fever. Chest computed tomography (CT) revealed an infiltrative shadow. Two separate sputum cultures detected Aspergillus niger. Although we treated the patient with single and combined antifungal agents, the infiltrative shadow worsened. After obtaining sufficient informed consent from the patient, we switched him to an inhaled L-AMB. The infiltrative shadow subsequently improved. The patient has remained well for one year without exacerbation. We herein report the usefulness of inhaled L-AMB and oral VRCZ.

Keywords: Aspergillus niger; antifungal combination therapy; chronic progressive pulmonary aspergillosis; fungus ball; inhaled liposomal amphotericin B.

Publication types

  • Case Reports

MeSH terms

  • Amphotericin B
  • Antifungal Agents* / therapeutic use
  • Humans
  • Male
  • Middle Aged
  • Pulmonary Aspergillosis* / diagnostic imaging
  • Pulmonary Aspergillosis* / drug therapy
  • Voriconazole


  • Antifungal Agents
  • liposomal amphotericin B
  • Amphotericin B
  • Voriconazole